{"nctId":"NCT03097861","briefTitle":"Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo","startDateStruct":{"date":"2017-03-13","type":"ACTUAL"},"conditions":["Chronic Idiopathic Constipation"],"count":552,"armGroups":[{"label":"Lubiprostone Capsule","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lubiprostone"]},{"label":"Lubiprostone Sprinkle","type":"EXPERIMENTAL","interventionNames":["Drug: Lubiprostone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Lubiprostone","otherNames":["Amitiza"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Either has medically-confirmed diagnosis of chronic constipation (per Rome III), or meets the diagnosis as confirmed using the Rome III constipation module questionnaire during the Screening period.\n* Is male or female, 18 or older years of age\n* Should be on stable dose of fiber supplement or a concomitant medication for the indication of lowering blood pressure\n\nExclusion Criteria:\n\n* Has any gastrointestinal (GI) condition, other than constipation, affecting GI motility or defecation\n* Is unable to eat or drink, take oral medications, or to hold down oral medications due to vomiting","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Observed Spontaneous Bowel Movement (SBM) Count Within 1 Week","description":"Observed SBM count was based on the observed data reported in the electronic daily diary for the actual number of SBMs during the 1-week treatment period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":"0.692"},{"groupId":"OG001","value":"1.37","spread":"0.693"},{"groupId":"OG002","value":"1.35","spread":"0.720"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.68","spread":"2.164"},{"groupId":"OG001","value":"4.82","spread":"3.658"},{"groupId":"OG002","value":"5.74","spread":"3.786"}]}]}]},{"type":"SECONDARY","title":"Mean SBM Consistency Score Within 1 Week","description":"Stool consistency associated with SBMs was rated according to the 7-point Bristol Stool Form Scale (1-7) where 1 = Separate hard lumps, like nuts (hard to pass), 2 = Sausage-shaped but lumpy, 3 = Like a sausage but with cracks on the surface, 4 = Like a sausage or snake, smooth and soft, 5 = Soft blobs with clear-cut edges (passed easily), 6 = Fluffy pieces with ragged edges, a mushy stool, 7 = Watery, no solid pieces; entirely liquid. Scores in the mid-range of this scale indicate better stool consistency.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":"1.122"},{"groupId":"OG001","value":"2.39","spread":"1.211"},{"groupId":"OG002","value":"2.28","spread":"1.045"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.43","spread":"1.270"},{"groupId":"OG001","value":"3.94","spread":"1.516"},{"groupId":"OG002","value":"4.22","spread":"1.409"}]}]}]},{"type":"SECONDARY","title":"Mean SBM Straining Score Within 1 Week","description":"Bowel straining associated with SBMs was rated on a scale of 0-4 where 0 = Absent, 1 = Mild, 2 = Moderate, 3 = Severe, 4 = Very severe. Higher score indicates more straining, so a worse condition.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":"0.739"},{"groupId":"OG001","value":"2.31","spread":"0.911"},{"groupId":"OG002","value":"2.40","spread":"0.892"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"0.871"},{"groupId":"OG001","value":"1.45","spread":"0.937"},{"groupId":"OG002","value":"1.19","spread":"0.917"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) is any untoward medical occurrence (including clinically significant changes in laboratory values or other clinical tests) experienced by a participant administered a pharmaceutical product regardless of causal relationship with the treatment. A TEAE is an episode which occur after the administration of the first dose of study medication and within 7 days after final dose.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":143},"commonTop":["Diarrhea","Headache","Nausea","Abdominal pain","Vomiting"]}}}